Doug Doerfler, chief executive of Inc (), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer disease.
Doerfler adds they're in active discussions with the US Food & Drug Administration to begin the study later this year of MCY-M11, which is based on its CARMA technology.
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY TO US PERSONS, AS DEFINED IN REGULATIONS PROMULGATED UNDER THE US SECURITIES ACT 1933, AS AMENDED (THE “US SECURITIES ACT”), OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR PUBLICATION WOULD BE UNLAWFUL.”
Meet Great Boulder Resources Ltd, Mainstream Group Holdings Ltd, Blackstone Minerals Ltd, Pacific American Coal Ltd and Reward Minerals Ltd at our event,
Sydney , 19 November 2018.
Register here »